Gilead Sciences Total Cost of Revenue decreased by 11.0% to $1.45B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.2%, from $1.54B to $1.45B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows relatively stable performance with a -1.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.39B | $1.22B | $2.63B | $1.42B | $1.44B | $1.40B | $1.40B | $1.40B | $1.44B | $1.57B | $2.09B | $1.55B | $1.54B | $1.57B | $1.58B | $1.54B | $1.50B | $1.57B | $1.62B | $1.45B |
| QoQ Change | — | -12.0% | +114.8% | -45.8% | +1.3% | -3.3% | +0.1% | +0.4% | +2.9% | +8.5% | +33.5% | -25.7% | -0.5% | +1.9% | +0.4% | -2.6% | -2.5% | +4.5% | +3.5% | -11.0% |
| YoY Change | — | — | — | — | +3.7% | +14.1% | -46.9% | -1.6% | +0.0% | +12.2% | +49.7% | +10.8% | +7.1% | +0.6% | -24.4% | -0.8% | -2.8% | -0.3% | +2.7% | -6.2% |